Stiripentol for dravet syndrome: is it worth it? - PubMed (original) (raw)

Stiripentol for dravet syndrome: is it worth it?

Eric Kossoff. Epilepsy Curr. 2014 Jan.

No abstract available

PubMed Disclaimer

Similar articles

References

    1. Scheffer IE. Diagnosis and long-term course of Dravet syndrome. Eur J Paediatr Neurol. 2012;16(suppl 1):S5–S8. - PubMed
    1. Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia. 2011;52(suppl 2):72–75. - PubMed
    1. Laux L, Blackford R. The ketogenic diet in Dravet syndrome. J Child Neurol. 2013;8:1041–1044. - PubMed
    1. Levy RH, Lin HS, Blehaut HM, Tor JA. Pharmacokinetics of stiripentol in normal man: Evidence of nonlinearity. J Clin Pharmacol. 1983;23:523–533. - PubMed
    1. Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, Dulac O, Pons G. Stiripentol in severe myoclonic epilepsy in infancy: A randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356:1638–1642. - PubMed

LinkOut - more resources